Efficacy of peripartum antiviral treatment for hepatic failure due to hepatitis B virus

[Guest guest]

http://www.ijgo.org/article/PIIS0020729211001688/abstract?rss=yes

Article in Press

Efficacy of peripartum antiviral treatment for hepatic failure due to hepatitis

B virus

Minmin Yu

, Ying Ji

, Hongxiu Jiang

, Lili Ju

, Kaihua Wu

, Naiying Kan

Received 22 October 2010; received in revised form 30 January 2011; accepted 4

April 2011. published online 18 May 2011.

Corrected Proof

Abstract

Objective

To investigate the efficacy of oral nucleosides in preventing hepatic failure

during pregnancy (HFP) caused by hepatitis B virus (HBV) infection.

Methods

Besides receiving standard treatment, 70 women with HFP caused by HBV infection

joined a study group (n=40) or a control group (n=30) according to their

preference. In the study group, 14 women were given lamivudine in the third

trimester and an antiviral treatment was continued postpartum. The 26 remaining

patients were treated postpartum only, with lamivudine (n=16) or entecavir

(n=10).

Results

In the study group, the values for serum HBV DNA and hepatitis B envelope

antigen were markedly lower at 1 and 2months than they were at baseline (P<0.001

and P<0.001, respectively). Moreover, the HBV DNA values at 1 and 2months were

significantly lower in the study than in the control group (P<0.05). Overall

mortality and incidence of intrauterine infection were also significantly lower

in the study group (P<0.05). No newborns had any apparent abnormalities in

either group.

Conclusion

Treatment with nucleosides suppressed the replication of HBV DNA and led to

biochemical improvement. It also reduced maternal mortality and safely decreased

mother-to-child HBV transmission.

[Guest guest]

http://www.ijgo.org/article/PIIS0020729211001688/abstract?rss=yes

Article in Press

Efficacy of peripartum antiviral treatment for hepatic failure due to hepatitis

B virus

Minmin Yu

, Ying Ji

, Hongxiu Jiang

, Lili Ju

, Kaihua Wu

, Naiying Kan

Received 22 October 2010; received in revised form 30 January 2011; accepted 4

April 2011. published online 18 May 2011.

Corrected Proof

Abstract

Objective

To investigate the efficacy of oral nucleosides in preventing hepatic failure

during pregnancy (HFP) caused by hepatitis B virus (HBV) infection.

Methods

Besides receiving standard treatment, 70 women with HFP caused by HBV infection

joined a study group (n=40) or a control group (n=30) according to their

preference. In the study group, 14 women were given lamivudine in the third

trimester and an antiviral treatment was continued postpartum. The 26 remaining

patients were treated postpartum only, with lamivudine (n=16) or entecavir

(n=10).

Results

In the study group, the values for serum HBV DNA and hepatitis B envelope

antigen were markedly lower at 1 and 2months than they were at baseline (P<0.001

and P<0.001, respectively). Moreover, the HBV DNA values at 1 and 2months were

significantly lower in the study than in the control group (P<0.05). Overall

mortality and incidence of intrauterine infection were also significantly lower

in the study group (P<0.05). No newborns had any apparent abnormalities in

either group.

Conclusion

Treatment with nucleosides suppressed the replication of HBV DNA and led to

biochemical improvement. It also reduced maternal mortality and safely decreased

mother-to-child HBV transmission.